4.7 Article

Synergistic Amplification of Ferroptosis with Liposomal Oxidation Catalyst and Gpx4 Inhibitor for Enhanced Cancer Therapy

Journal

ADVANCED HEALTHCARE MATERIALS
Volume -, Issue -, Pages -

Publisher

WILEY
DOI: 10.1002/adhm.202301292

Keywords

ferric ammonium citrate; ferroptosis; lipid peroxide; liposomes; sorafenib

Ask authors/readers for more resources

Ferroptosis can cause cell death through excessive accumulation of lipid peroxide (LPO) and has potential for cancer therapy. However, efficient strategies are facing challenges due to insufficient H2O2, high pH value, and high redox level of tumor cells.
As a distinctly different way from apoptosis, ferroptosis can cause cell death through excessive accumulation of lipid peroxide (LPO) and show great potential for cancer therapy. However, efficient strategies for ferroptosis therapy are still facing great challenges, mainly due to insufficient endogenous H2O2 or relatively high pH value for Fenton reaction-dependent ferroptosis, and the high redox level of tumor cells attenuates the oxidation therapy. Herein, an efficient lipid-based delivery system to load oxidation catalyst and glutathione peroxidase 4 (Gpx4) inhibitor is orchestrated, intending to amplify Fenton reaction-independent ferroptosis by bidirectional regulation of LPO accumulation. Ferric ammonium citrate (FAC), Gpx4 inhibitor sorafenib (SF), and unsaturated lipids are constructed into mPEG(2K)-DSPE-modified liposomes (Lip@SF & FAC). Influenced by the high level of intratumoral glutathione, FAC can be converted into Fe2+, and subsequently the formed iron redox pair (Fe2+/Fe3+) catalyzes unsaturated phospholipids of liposomes into LPO via a Fenton reaction-independent manner. Meanwhile, SF can downregulate LPO reduction by inhibiting Gpx4 activation. In vitro and in vivo antitumor experiments show that Lip@SF & FAC induces massive LPO accumulation in tumor cells and ultimately exhibits strong tumor-killing ability with negligible side effect. Consequently, this two-pronged approach provides a new ferroptosis strategy for predominant LPO accumulation and enhanced cancer therapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available